Evidence map›Paper›PMID 32333626›Full record

ArticleThe oncologist2020

Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals.

Benlong Yang, Guosheng Ren, Erwei Song, Da Pan, Jing Zhang, Yongsheng Wang, Ning Liao, Jinhai Tang, Xiang Wang, Shude Cui and 10 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07593846 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A National Multicenter, Prospective, Cohort Study Comparing Delayed Endoscopic Direct-to-Implant Breast Reconstruction Via Axillary Approach With the Two-Stage Expander-to-Implant Breast Reconstruction Following Simple Mastectomy

TypeinterventionalSponsorWest China HospitalRan2026 to 2028Enrolled412ConditionsBreast CancerArmsDelayed endoscopic direct-to-implant breast reconstruction, Two-stage expander-to-implant breast reconstruction
NCT07757074 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A National Multicenter, Prospective Cohort Study on Delayed Endoscopic Direct-to-Implant Breast Reconstruction Via Transaxillary Approach Versus Latissimus Dorsi ± Implant Breast Reconstruction Following Mastectomy

TypeobservationalSponsorDu ZhengguiRan2026 to 2028Enrolled268ConditionsBreast CancerArmsSurgery options
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Decision-making driving factors in breast reconstruction among premenopausal breast cancer patients in China: a Q-methodology study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  8. [Advances in application of tissue expansion technology in breast reconstruction].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. [Application of dual chamber round tissue expander in immediate breast reconstruction].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 1 country.

Benlong YangDepartment of Breast Surgery, Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Guosheng RenDepartment of Breast Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Erwei SongBreast Tumor Center, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Da PanDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China.
Jing ZhangDepartment of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.
Yongsheng WangDepartment of Breast Cancer Center, Shandong Cancer Hospital, Jinan, People's Republic of China.
Ning LiaoDepartment of Breast Cancer, Cancer Center, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
Jinhai TangDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Xiang WangDepartment of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Shude CuiDepartment of Breast Cancer, Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Feng JinDepartment of Breast Surgery, First Hospital of China Medical University, Shenyang, Liaoning Province, People's Republic of China.
Cuizhi GengResearch Center and Tumor Research Institute, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
Qiang SunDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, People's Republic of China.
Hongyuan LiDepartment of Breast Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Zhimin FanDepartment of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China.
Xuchen CaoDepartment of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.
Haibo WangBreast Center, Qingdao University Affiliated Hospital, Qingdao, Shandong Province, People's Republic of China.
Shu WangBreast Disease Center, Peking University People's Hospital, Beijing, People's Republic of China.
Zhimin ShaoDepartment of Breast Surgery, Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Jiong WuDepartment of Breast Surgery, Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.ORCID https://orcid.org/0000-0002-8103-0505
Chinese Academy of Medical Sciences & Peking Union Medical College · CNShanghai Cancer Institute · CNTianjin Medical University Cancer Institute and Hospital · CNChina Medical University · CNChongqing Medical University · CNFirst Affiliated Hospital of Chongqing Medical University · CNFourth Hospital of Hebei Medical University · CNFudan University Shanghai Cancer Center · CNGuangdong General Hospital · CNHenan Cancer Hospital · CNJilin University · CNNanjing Medical University · CNPeking University · CNQingdao University · CNShandong First Medical University · CNSun Yat-sen Memorial Hospital · CNThird Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are limited nationwide data regarding breast cancer surgery in China. The Chinese Anti-Cancer Association's Committee of Breast Cancer Society and the Chinese Society of Breast Surgeons conducted a nationwide survey to examine the use of and barriers associated with surgical options among patients with breast cancer.

methodsSurveys were sent via e-mail to the directors of 110 centers that performed at least 200 breast cancer operations in 2017. The electronic questionnaire contained 183 questions and covered six aspects, including demographic information about the hospitals and surgeons, surgical practice, and application of breast reconstruction.

resultsThe selected hospitals were from 31 provinces or municipalities. The overall proportion of breast-conserving surgery (BCS) was 22%. Local gross domestic product was significantly related to the rate of BCS (p = .046). Sentinel lymph node biopsy was performed routinely in 76% of hospitals. Only 14.5% (16/110) of hospitals used the dual-tracer method, including radioisotopes. For patients with cN0 disease receiving BCS with one or two positive sentinel lymph nodes, 20% (22/110) of hospitals accepted omitting axillary lymph node dissection (ALND). For patients who underwent mastectomy, only 4% (4/110) of hospitals accepted omitting ALND. There was an obvious polarization trend in the proportion of oncoplastic breast-conserving surgery (OPS); 35/110 (32%) performed OPS in fewer than 10% of cases, whereas 36/110 (33%) performed OPS in more than 50% of cases. OPS was more likely to be performed in academic hospitals. Volume displacement was more commonly used than volume replacement (p < .001). Breast reconstruction was routinely performed in 96/110 (87%) of hospitals, 62% of which involved cooperation with the plastic surgery department. Factors influencing breast reconstruction after mastectomy included the establishment of a plastic surgery department, regional economy, and cooperation between the plastic and general surgery departments. Overall, the proportion of breast reconstruction procedures after mastectomy was 10.7%, with 70% being implant-based reconstruction, 17% autologous tissue reconstruction, and 13% a combination. Overall, 22% of the hospitals predominantly performed immediate breast reconstruction. For delayed reconstruction, two-stage implant-based breast reconstruction was the first choice for 46% of centers, whereas 20% of centers chose autologous reconstruction. Among the 96 centers that performed autologous-based reconstruction, 96% performed latissimus dorsi flap reconstruction, 65% performed transverse rectus abdominis musculocutaneous flap reconstruction, and 45% used deep inferior epigastric artery perforator flaps.

conclusionThe results are of great value for promoting the implementation of a consensus on diagnostic and treatment standards, development of guidelines for breast cancer, and training of breast specialists. IMPLICATIONS FOR PRACTICE: This study aimed to establish comprehensive baseline data on the status of current breast cancer treatment in China by presenting the statistics on clinical treatments and surgeries, the distribution of clinical stages, and the demographic characteristics of patients. This report is based on a survey conducted by the Chinese Anti-Cancer Association's Committee of Breast Cancer Society and the Chinese Society of Breast Surgeons, which examined the use of breast cancer surgical options in hospitals all over the country and the factors hindering the adoption of procedures and techniques. This study makes a significant contribution to the literature because there are limited nationwide data regarding breast cancer surgery in China.

Indexed as

Breast NeoplasmsMastectomyChinaCross-Sectional StudiesFemaleHospitalsHumansBreast cancerBreast reconstructionBreast surgeryChinaQuestionnaire survey

Identifiers

PMID32333626
PMCPMC7543333
OpenAlexW3018777185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.